Rhythm Pharma CFO sells 7,954 shares in plan

Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.

Accepted by SEC EDGAR 02/19/2026 - 09:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 7,954 shares

Net Sell 9 txns

Insider Smith Hunter C

Role Chief Financial Officer

Sold 7,954 shs ($806K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,308	$100.2698	$131K
Sale	Common Stock	1,692	$100.9189	$171K
Sale	Common Stock	800	$102.0951	$82K
Sale	Common Stock	585	$103.2828	$60K
Sale	Common Stock	1,200	$99.415	$119K
Sale	Common Stock	200	$100.52	$20K
Sale	Common Stock	900	$101.70	$92K
Sale	Common Stock	1,069	$103.0024	$110K
Sale	Common Stock	200	$103.84	$21K

Holdings After Transaction: Common Stock — 110,512 shares (Direct)

Footnotes (9)

1. F1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
2. F2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rhythm Pharmaceuticals (RYTM) disclose in this Form 4?

Rhythm Pharmaceuticals disclosed that its Chief Financial Officer, Hunter C. Smith, sold 7,954 shares of common stock in open-market transactions. These sales occurred on February 17 and 19, 2026, under a previously adopted Rule 10b5-1 trading plan.

How many Rhythm Pharmaceuticals (RYTM) shares did the CFO sell and at what prices?

The CFO sold 7,954 shares of Rhythm Pharmaceuticals common stock. Individual trade prices ranged from $99.25 to $103.50 per share, with reported figures often representing weighted average prices across multiple transactions within those ranges.

Does the Rhythm Pharmaceuticals (RYTM) CFO still hold shares after these sales?

Yes, after completing the reported open-market sales, Chief Financial Officer Hunter C. Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock, according to the Form 4 ownership figures following the final transaction.

Were the Rhythm Pharmaceuticals (RYTM) CFO’s stock sales pre-planned?

Yes. The filing states that the reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Hunter C. Smith on February 28, 2025, indicating the transactions were pre-arranged rather than discretionary trades.

Over what dates did the Rhythm Pharmaceuticals (RYTM) CFO sell shares?

The reported open-market sales took place on February 17, 2026, and February 19, 2026. Multiple trades occurred on each day at different prices, with the Form 4 providing weighted average prices and price ranges for those transactions.

How are the share prices reported in the Rhythm Pharmaceuticals (RYTM) Form 4?

The prices shown are weighted average prices for groups of trades. Footnotes explain that shares were sold in multiple transactions within specified price ranges, and detailed, trade-by-trade pricing information is available upon request from the issuer or the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Hunter C

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		1,200	D	$99.415(2)	117,266	D
Common Stock	02/17/2026		S(1)		200	D	$100.52(3)	117,066	D
Common Stock	02/17/2026		S(1)		900	D	$101.7(4)	116,166	D
Common Stock	02/17/2026		S(1)		1,069	D	$103.0024(5)	115,097	D
Common Stock	02/17/2026		S(1)		200	D	$103.84	114,897	D
Common Stock	02/19/2026		S(1)		1,308	D	$100.2698(6)	113,589	D
Common Stock	02/19/2026		S(1)		1,692	D	$100.9189(7)	111,897	D
Common Stock	02/19/2026		S(1)		800	D	$102.0951(8)	111,097	D
Common Stock	02/19/2026		S(1)		585	D	$103.2828(9)	110,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.

2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.